We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$37M
1-Year Est. Return
63.54%
This Fund
S&P 500
This Quarter
Est. Return
+6.01%
1 Year Est. Return
+63.54%
3 Year Est. Return
+38.32%
5 Year Est. Return
+47.02%
10 Year Est. Return
+2,091.28%
AUM
$195M
AUM Growth
+$1.58M
(+0.82%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
15.76%
Top 10 Holdings %
Top 10 Hldgs %
32.39%
Holding
95
New
32
Increased
19
Reduced
11
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$7.51M |
| 2 |
SPNC
Spectranetics Corp
SPNC
|
+$6.98M |
| 3 |
Pfizer
PFE
|
+$4.9M |
| 4 |
Stryker
SYK
|
+$4.74M |
| 5 |
AbbVie
ABBV
|
+$3.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$9.93M |
| 2 |
Boston Scientific
BSX
|
+$5.18M |
| 3 |
Humana
HUM
|
+$4.9M |
| 4 |
CONMED
CNMD
|
+$4.72M |
| 5 |
AGN
Allergan plc
AGN
|
+$3.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.86% |
| 2 | Miscellaneous | 25.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cigna
CI
$74.1B
| $9.36M | 4.79% |
65,000
+26,000
| +67% | +$3.59M |
|
|
2
Universal Health Services
UHS
$10.7B
| $8.71M | 4.46% |
+60,000
| New | +$7.51M |
|
3
CALL
Teleflex
TFX
$5.42B
| $6.77M | 3.47% |
50,000
+10,000
| +25% | +$1.27M |
|
|
4
Teleflex
TFX
$5.42B
| $6.54M | 3.35% |
48,800
+13,800
| +39% | +$1.75M |
|
|
ALIM
5
DELISTED
Alimera Sciences
ALIM
| $6M | 3.07% |
82,920
+8,521
| +11% | +$588K |
|
|
SIEN
6
DELISTED
Sientra, Inc.
SIEN
| $5.61M | 2.87% |
24,140
-3,170
| -12% | -$648K |
|
|
NUVA
7
DELISTED
NuVasive, Inc.
NUVA
| $5.18M | 2.65% |
94,139
+14,339
| +18% | +$670K |
|
|
8
Pfizer
PFE
$157B
| $5.14M | 2.63% |
+150,195
| New | +$4.9M |
|
|
9
Stryker
SYK
$109B
| $5.11M | 2.62% |
+50,000
| New | +$4.74M |
|
10
CALL
Thermo Fisher Scientific
TMO
$240B
| $4.87M | 2.49% |
37,500
+7,500
| +25% | +$978K |
|
11
Cooper Companies
COO
$10.4B
| $4.42M | 2.26% |
100,000
+40,000
| +67% | +$1.8M |
|
|
SPNC
12
DELISTED
Spectranetics Corp
SPNC
| $4.28M | 2.19% |
+250,000
| New | +$6.98M |
|
|
13
Boston Scientific
BSX
$63.6B
| $4.08M | 2.09% |
235,000
-290,000
| -55% | -$5.18M |
|
|
14
AbbVie
ABBV
$464B
| $4.02M | 2.06% |
+57,375
| New | +$3.75M |
|
15
Smith & Nephew
SNN
$11.6B
| $3.89M | 1.99% |
105,000
-17,500
| -14% | -$608K |
|
16
CALL
Agilent Technologies
A
$43.3B
| $3.86M | 1.97% |
100,000
+40,000
| +67% | +$1.66M |
|
17
Edwards Lifesciences
EW
$51.5B
| $3.8M | 1.95% |
150,000
-90,000
| -38% | -$2.03M |
|
18
Vanda Pharmaceuticals
VNDA
$302M
| $3.76M | 1.93% |
307,500
+227,117
| +283% | +$2.45M |
|
|
NXTM
19
DELISTED
NxStage Medical Inc.
NXTM
| $3.72M | 1.9% |
260,200
+156,084
| +150% | +$2.64M |
|
|
ACH
20
Accendra Health
ACH
$82.3M
| $3.69M | 1.89% |
+105,000
| New | +$3.54M |
|
|
CYBX
21
DELISTED
CYBERONICS INC
CYBX
| $3.68M | 1.89% |
60,000
+30,000
| +100% | +$1.89M |
|
22
Jazz Pharmaceuticals
JAZZ
$15.8B
| $3.46M | 1.77% |
18,000
-14,500
| -45% | -$2.6M |
|
23
Insulet
PODD
$9.75B
| $3.39M | 1.73% |
100,000
-70,900
| -41% | -$2.09M |
|
|
CPHD
24
DELISTED
Cepheid Inc
CPHD
| $3.33M | 1.71% |
+60,000
| New | +$3.42M |
|
25
Bristol-Myers Squibb
BMY
$130B
| $3.32M | 1.7% |
+50,625
| New | +$3.34M |
|
Similar funds
MAM
GSEP
CTC
XA
YEPI
PEP
CP
WTG
Pura Vida Investments's Q2 2015 Portfolio in Review
As of Q2 2015, Pura Vida Investments held 95 positions worth $195M, up 0.82% from $194M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Pura Vida Investments deployed $30.8M of net new capital in Q2 2015, opening 32 new positions and adding to 19 existing holdings. Its largest new stake was Universal Health Services: 60,000 shares worth $8.71M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 60% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Boston Scientific, an estimated $5.18M trimmed.
- Pura Vida Investments's largest Q2 2015 buy was Universal Health Services: 60,000 shares worth $8.71M.
- Pura Vida Investments added most to Cigna in Q2 2015, an estimated $3.59M increase.
- Pura Vida Investments's biggest Q2 2015 reduction was Boston Scientific, cutting an estimated $5.18M.
- Pura Vida Investments fully exited Baxter International in Q2 2015, selling an estimated $9.93M.
- Pura Vida Investments's ten largest holdings make up 32% of its $195M portfolio in Q2 2015.
- Pura Vida Investments opened 32 new positions and closed 27 in Q2 2015.
- Pura Vida Investments's portfolio value rose 0.82% quarter-over-quarter to $195M.
Based on Pura Vida Investments's 13F filing for Q2 2015, filed 14 Aug 2015.